
Shares of Florida-based drug developer MIRA Pharmaceuticals MIRA.O fall 8.6% to $1.17 premarket
Agrees to buy privately held Delaware-based SKNY Pharmaceuticals in a stock deal to add experimental weight-loss drug candidate - regulatory filing
SKNY-1 is an experimental oral drug in preclinical development for weight-loss and smoking cessation
Says SKNY will contribute $5 million in cash or assets at close
MIRA marginally up in the past 12 months